Quarterly Results announcement form

SIIC Medical Science and Technology (Group) Limited					
8018					
31/12/2001					
xtracted informati	ion from and should be read	in conjunct	ion with		
, which can be vie	wed on the GEM website at l	nttp://www.	hkgem.com		
	(Unaudited) (Unaudited)				
Current Period (dd/mm/yyyy)		Last Corresponding Period			
· —			. — . — . — . — . — .		
ω	30/00/2001	10 <u> </u>	30/00/2000		
	HK\$'000		HKS	\$'000	
:	339,402		249,415		
:	71,865		55,480		
:	0		-1,107		
: <u></u>	17,933		11	,391	
: <u></u>	-27		0		
: <u></u>	198,914		32,986		
:	503.03	%			
: . <u> </u>	32.1 cents		5.3 cents		
: . <u></u> .	N/A		N/A		
: . <u> </u>	0			0	
: <u></u> .	198,914		32,986		
: . <u></u> .	Nil		Nil		
: . <u>.</u> .	Nil		Nil		
: . <u></u> .	N/A	to	N/A	bdi	
: . <u></u> .	N/A				
: . <u> </u>	N/A	to	N/A	bdi	
: . <u> </u>	N/A				
: . <u></u> .	N/A	to	N/A (bdi: both days in	bdi	
	8018 31/12/200 xtracted informati , which can be vie	31/12/2001	Sol Sol	Sol Sol	

Remarks

For and on behalf of SIIC Medical Science and Technology (Group) Limited

Signature:

Name : Wong Mei Ling, Marina

Title : Company Secretary

Responsibility statement

The directors of the Company (the "Directors") as at the date hereof hereby collectively and individually accept full responsibility for the accuracy of the information contained in this results announcement form (the "Information") and confirm, having made all reasonable inquiries, that to the best of their knowledge and belief the Information are accurate and complete in all material respects and not misleading and that there are no other matters the omission of which would make the Information herein inaccurate or misleading. The Directors acknowledge that the Stock Exchange has no responsibility whatsoever with regard to the Information and undertake to indemnify the Exchange against all liability incurred and all losses suffered by the Exchange in connection with or relating to the Information.

1. Basis of preparation

Shanghai Jahwa United Co., Ltd. (上海家化聯合股份有限公司) ("Shanghai Jahwa"), previously a jointly controlled entity of the Group, was listed on the Shanghai Stock Exchange A Shares Market on 15th March 2001 and became an associate since then. In accordance with Hong Kong Statements of Standard Accounting Practice 10 "Accounting for investments in associates", the Company should include only published financial information of its listed associate in its financial statements. Shanghai Jahwa did not publish its financial statements for the period ended 31st March 2001. As a result, the income statement of the Group for the three months ended 30th June 2001 included the sharing of results of Shanghai Jahwa for the six months period from 1st January 2001 to 30th June 2001.

2. Turnover

Turnover represented the net amounts received and receivable for goods sold by the Group to outside customers during the period.

3. Profit from operation

During the period, the profit from operations was principally come from Chia Tai Qingchunbao Pharmaceutical Co., Ltd. (正大青春寶藥業有限公司).

4. Share of Profit/(Loss) of Associates

Pursuant to basis of preparation in note 1, share of profit of an associated company of the Group for the three months ended 30th June 2001 included the sharing of results of Shanghai Jahwa for the six months period from 1st January 2001 to 30th June 2001.

5. Profit/(Loss) after Taxation & Minority Interests

Profit/(Loss) after taxation and minority interests included approximately HK\$155 million from gain on deemed disposal of interests in a jointly controlled entity. Gain on deemed disposal of interests in a jointly controlled entity represented the exceptional gain on deemed disposal by the Group's interest in Shanghai Jahwa diluted from 40% to 28.15% after the listing of Shanghai Jahwa's shares on the Shanghai Stock Exchange A Shares Market.

6. Earnings per share

The calculation of the basic earnings per share is based on the profit for the six months and three months ended 30th June 2001 of HK\$198,914,000 and HK\$26,931,000 respectively (six months and three months ended 30th June 2000: HK\$32,986,000 and HK\$19,440,000) and the weighted average of 620,000,000 shares (six months and three months ended 30th June 2000: 620,000,000 shares) in issue for the six months and three months ended 30th June 2001.

Diluted earnings per share is not presented as there were no dilutive potential ordinary shares in existence during the periods.

7. Comparative Figures

Certain comparative figures have been reclassified in order to conform with current period's presentation.